XTALPI's stock soared 5.09% during intraday trading on Thursday. The significant upward movement reflects strong investor sentiment following a series of positive corporate developments.

The company announced significant progress in its collaboration with DoveTree, with one pan-cancer high-value asset entering the pre-IND preparation stage. The milestone triggered an additional payment of $19 million to XTALPI under the agreement. Furthermore, the company's three co-founders voluntarily extended their share lock-up commitments by an additional 12 months until June 2027, signaling strong confidence in the firm's long-term prospects.

The company also recently showcased its AI-driven drug discovery platforms, PepiX and Kodexia, at the TIDES USA conference, highlighting its expansion into multi-modality drug development. These combined factors provided a clear catalyst for the stock's strong performance during the session.